Bristol-Myers Squibb Company (FRA:BRM)
Germany · Delayed Price · Currency is EUR | Market Cap | 78.24B |
| Revenue (ttm) | 40.62B |
| Net Income (ttm) | 4.30B |
| Shares Out | n/a |
| EPS (ttm) | 2.12 |
| PE Ratio | 18.20 |
| Forward PE | 7.02 |
| Dividend | 2.24 (5.83%) |
| Ex-Dividend Date | Jul 3, 2025 |
| Volume | 3,490 |
| Average Volume | 457 |
| Open | 37.61 |
| Previous Close | 37.87 |
| Day's Range | 37.60 - 38.42 |
| 52-Week Range | 37.00 - 58.51 |
| Beta | n/a |
| RSI | 34.05 |
| Earnings Date | Oct 30, 2025 |
About FRA:BRM
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthrit... [Read more]
News
Bristol Myers Squibb Enters Oversold Territory
The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important ...
Interesting BMY Put And Call Options For November 7th
Investors in Bristol Myers Squibb Co. (Symbol: BMY) saw new options begin trading today, for the November 7th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BM...
Bristol Myers Squibb (BMY) Expands Discounted Drug Offerings
Bristol Myers Squibb (BMY) Expands Discounted Drug Offerings
Bristol Myers (BMY) Expands Direct Patient Access to Key Medications
Bristol Myers (BMY) Expands Direct Patient Access to Key Medications
Bristol Myers (BMY) Advances in Pulmonary Fibrosis Treatment
Bristol Myers (BMY) Advances in Pulmonary Fibrosis Treatment
Bristol Myers expands DTC offerings as Trump deadline to lower drug prices looms
Bristol-Myers Squibb (BMY) Faces Extended Losses Amid Analyst Optimism
Bristol-Myers Squibb (BMY) Faces Extended Losses Amid Analyst Optimism
Bristol-Myers Squibb ends in red for seventh straight session
Bristol Myers Squibb Franchise Gains Momentum With Phase 3 Results In Multiple Myeloma Patients
Bristol Myers Squibb & Co. (NYSE: BMY) on Tuesday announced results from the Phase 3 EXCALIBER-RRMM study evaluating iberdomide, an investigational cereblon E3 ligase modulator (CELMoD), combined wit...
Bristol Myers Squibb (BMY) Reports Positive Trial Data for Iberdomide
Bristol Myers Squibb (BMY) Reports Positive Trial Data for Iberdomide
Bristol Myers reports positive results from multiple myeloma study
Bristol Myers (BMY) Reports Promising Phase 3 Study Results for Iberdomide in RRMM
Bristol Myers (BMY) Reports Promising Phase 3 Study Results for Iberdomide in RRMM
Bristol Myers Squibb Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies Demonstrated a Significant Improvement in Minimal Residual Disease Negativity Rates in Relapsed or Refractory Multiple Myeloma
Bristol Myers Squibb (NYSE: BMY) today announced that the Phase 3 EXCALIBER-RRMM study evaluating iberdomide, an investigational cereblon E3 ligase modulator (CELMoD), combined with standard therapies...
1 Reason to Buy Bristol Myers Squibb Stock
Find out why investors seeking passive income want shares of this dividend payer in their portfolio.
Bristol Myers Squibb Adopts Veeva Vault CRM To Enhance HCP Engagement
(RTTNews) - Veeva Systems (VEEV) announced that Bristol Myers Squibb - BMS has selected Veeva Vault CRM to advance its commercial operations and strengthen engagement with healthcare practitioners - H...
Bristol Myers (BMY) Commits to Veeva Vault CRM Platform
Bristol Myers (BMY) Commits to Veeva Vault CRM Platform
Bristol Myers Squibb (BMY) Embraces Veeva Vault CRM
Bristol Myers Squibb (BMY) Embraces Veeva Vault CRM
BMY Quantitative Stock Analysis
Below is Validea's guru fundamental report for BRISTOL-MYERS SQUIBB CO (BMY). Of the 22 guru strategies we follow, BMY rates highest using our Earnings Yield Investor model based on the published stra...
Bristol Myers Squibb: Buy This Deep Bargain Before The Market Wakes To Income
Can Bristol Myers Squibb's Restructuring Program Boost Earnings Growth?
Bristol Myers ramps up a $2.5B restructuring plan to cut costs, streamline operations, and offset pressure from generic competition.
Bristol-Myers Squibb (BMY) Declares Consistent Quarterly Dividend
Bristol-Myers Squibb (BMY) Declares Consistent Quarterly Dividend
J&J's experimental psoriasis drug shows promise against Bristol's treatment
Johnson & Johnson said its experimental psoriasis drug has shown superior skin clearance compared to Bristol Myers Squibb's Sotyktu in two head-to-head trials.
Bristol-Myers Squibb declares $0.62 dividend
Bristol Myers Squibb Announces Dividend
Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-two cents ($0.62) per share on the $0.10 par value common stock of the company. ...